Compare NLOP & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | CNTN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 178.5M |
| IPO Year | 2022 | 2021 |
| Metric | NLOP | CNTN |
|---|---|---|
| Price | $9.61 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 149.2K | ★ 835.5K |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $118,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.48 | $1.75 |
| 52 Week High | $30.26 | $5.27 |
| Indicator | NLOP | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 38.49 |
| Support Level | $9.51 | $1.75 |
| Resistance Level | $12.19 | $2.40 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 22.73 | 0.59 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.